Nuclear Medicine Communications最新文献

{"title":"The prognostic role of whole-body volumetric positron emission tomography/computed tomography parameters in treatment naive colorectal cancer patients with liver metastases.","authors":"Hüseyin Karaoğlan, Ferat Kepenek, Halil Kömek, İhsan Kaplan, Ömer Yeprem, Ridvan Kaya, Yunus Güzel, Veysi Şenses, Fulya Kaya İpek, Canan Can","doi":"10.1097/MNM.0000000000001915","DOIUrl":"10.1097/MNM.0000000000001915","url":null,"abstract":"<p><strong>Purpose: </strong>The present study aimed to predict the prognostic role of quantitative 18 F-fluorodeoxyglucose PET/computed tomography parameters such as maximum standardized uptake value (SUV max ), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) obtained from primary tumor, lymph node metastases, and liver metastasis (LM) in patients with colorectal LM (CLM).</p><p><strong>Material and method: </strong>The research was designed as a retrospective study and 66 patients with CLM were enrolled between January 2017 and December 2018. Primary tumor SUV max (PSUV max ), liver SUV max (LSUV max ), and lymph node SUV max (LnSUV max ) values obtained from the primary tumor, liver, and lymph nodes were recorded. In addition, total MTV (TMTV) and total TLG (TTLG) values were obtained by summing the values obtained from the primary tumor (PMTV and PTLG), lymph nodes (LnMTV and LnTLG), and liver (LMTV and LTLG). Univariate and multivariate Cox regression analysis was used to measure the effects of prognostic variables on mortality and survival.</p><p><strong>Result: </strong>In univariate Cox regression analysis, PMTV ( P  = 0.001), LnMTV ( P  = 0.008), LnTLG ( P  = 0.008), LnSUV max ( P  = 0.047), and TTLG ( P  = 0.038) were identified as prognostic factors for overall survival. No statistically significant relationship was found between MTV and TLG values of LM and overall survival. In multivariate analysis, PMTV ( P  = 0.022) was identified as an independent prognostic factor.</p><p><strong>Conclusion: </strong>In conclusion, our study demonstrated that the PMTV value used in evaluating treatment-naive patients diagnosed with CLM is an independent prognostic factor for survival. Our results need to be confirmed with more studies involving more patients.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"55-59"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of exclusive rib lesions detected by [ 68 Ga]Ga-PSMA-11 PET/CT.","authors":"Marine Stoffels, François Cousin, Maréva Lamande, Chloé Denis, David Waltregny, Roland Hustinx, Brieuc Sautois, Nadia Withofs","doi":"10.1097/MNM.0000000000001919","DOIUrl":"10.1097/MNM.0000000000001919","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to characterize exclusive costal lesions detected by 68 Gallium-labelled prostate-specific membrane antigen ([ 68 Ga]Ga-PSMA-11) PET/computed tomography (CT) at initial staging or biochemical recurrence (BCR) in prostate cancer (PCa) patients, and to identify clinical and/or PET/CT criteria associated with benign and malignant lesions.</p><p><strong>Methods: </strong>We retrospectively identified 54 patients with PCa who underwent [ 68 Ga]Ga-PSMA-11 PET/CT for initial staging ( N  = 39) or BCR ( N  = 15) and whose reports described rib lesions, at the exclusion of any other lesions, whether doubtful, suspicious, or established. Posttherapy prostate-specific antigen (PSA) levels were used to determine whether those lesions were benign or malignant. Each patient's prostate-specific membrane antigen PET/CT report was classified as true positive, true negative, false positive, or false negative based on the posttherapy PSA level. We then assessed whether any clinical and/or PET/CT criteria could help differentiate benign from malignant lesions, and if any criteria were misleading.</p><p><strong>Results: </strong>Among the 54 patients, 46 (85.2%) had 64 benign costal lesions, and eight (14.8%) had 10 malignant lesions. PET/CT reports indicated rib lesions as benign/equivocal in 38/54 (55.6%) patients and malignant in 16/54 (29.6%). Benign features on CT were the only parameter significantly associated with the final diagnosis. Factors such as patient age, maximum standardized uptake value of lesions, lesion dispersion, and malignant features described on CT were found to be misleading when deciding the malignant or benign status.</p><p><strong>Conclusion: </strong>Most exclusive costal lesions detected by [ 68 Ga]Ga-PSMA-11 PET/CT are benign. Apart from specific benign CT features, no clinical or PET/CT criteria reliably differentiate benign from malignant costal lesions.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"95-105"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of baseline 18 F-FDG PET/CT and peripheral blood inflammatory markers for aggressive lymphoma in non-Hodgkin's lymphoma.","authors":"Qichen Jia, Aihui Wang, Yuang Liu, Yishuo Fan, Xiaohong Zhou, Yupeng Liu, Liying Wu, Xiaohui Ouyang, Jiagui Su, Baolong Shi, Xiaofei Liu","doi":"10.1097/MNM.0000000000001912","DOIUrl":"10.1097/MNM.0000000000001912","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to investigate the diagnostic value of baseline F18 fluorodeoxyglucose (FDG) PET/computed tomography (CT) parameters and peripheral blood inflammatory markers in aggressive lymphoma of non-Hodgkin lymphoma (NHL) and the correlation between peripheral blood inflammatory markers and maximum standardized uptake value (SUV max ).</p><p><strong>Patients and methods: </strong>We conducted a retrospective analysis including 121 patients with NHL. Patients were divided into aggressive lymphoma group and indolent lymphoma group. Mann-Whitney U test, chi-square test and multivariate stepwise logistic regression were used to analyse. Subsequently, receiver operating characteristic (ROC) curve analysis was conducted to evaluate the diagnostic performance. Additionally, Spearman correlation analysis was utilized to explore the correlation between peripheral blood inflammatory markers and SUV max .</p><p><strong>Results: </strong>Leptin mass criterion uptake value (SUL) max , SUV max , SUV avg , SUV peak , focal SUV max /liver SUV max , focal SUV max / mediastinal SUV max , SUL avg , SUL peak , systemic immune-inflammation (SII), neutrophil ratio, total lesion glycolysis (TLG), neutrophils versus lymphocyte ratio (NLR), plateletto-lymphocyte ratio (PLR), lactate dehydrogenase (LDH) and lymphocyle ratio between two groups were statistically significant ( P  < 0.05). SUV max was an independent influencing factor, and the area under the ROC curve was 0.862. There was a positive correlation between the PLR and SUV max ( r  = 0.239; P  = 0.008).</p><p><strong>Conclusion: </strong>PET/CT parameters and peripheral blood inflammatory markers have certain value in the diagnosis of aggressive lymphoma in NHL, among which SUV max is an independent influencing marker and is positively correlated with PLR.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"60-66"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-center analysis of cardiac amyloidosis using 99m Tc-HMDP imaging for diagnosis and evaluation after tafamidis treatment.","authors":"Ryuta Egi, Yohji Matsusaka, Kaho Watanabe, Akira Seto, Ichiro Matsunari, Takahide Arai, Shintaro Nakano, Ichiei Kuji","doi":"10.1097/MNM.0000000000001922","DOIUrl":"10.1097/MNM.0000000000001922","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the diagnostic performance of 99m Tc-hydroxymethylene diphosphonate ( 99m Tc-HMDP) imaging for cardiac amyloidosis and to demonstrate changes in cardiac uptake of 99m Tc-HMDP after tafamidis treatment.</p><p><strong>Methods: </strong>Seventy-five patients with suspected cardiac amyloidosis who underwent 99m Tc-HMDP imaging were included. We compared visual Perugini grades and semiquantitative heart-to-contralateral (H/CL) area ratios, myocardial maximum standardized uptake value (SUVmax), and peak of SUV (SUVpeak) between cardiac transthyretin amyloidosis (ATTR) and amyloid light-chain amyloidosis (AL). Comparison of interobserver reproducibility between H/CL ratios and myocardial SUVmax/SUVpeak was performed. H/CL ratio of 99m Tc-HMDP and myocardial SUVmax/SUVpeak were compared before and after tafamidis administration for cardiac wild-type ATTR.</p><p><strong>Results: </strong>Among 75 patients, 20 patients (26.7%) were visually positive based on Perugini grade. Fifteen and three patients were pathologically identified as cardiac ATTR and AL, respectively. ATTR group ( n  = 15) had significantly higher H/CL ratios of 99m Tc-HMDP than AL group ( n  = 3) ( P  = 0.003). ATTR group ( n  = 15) had significantly higher myocardial SUVmax/SUVpeak of 99m Tc-HMDP than AL group ( n  = 2) ( P  = 0.015). Myocardial SUVmax/SUVpeak had better interobserver reproducibility than H/CL ratios. After tafamidis treatment for cardiac wild-type ATTR, the decrease in myocardial SUVpeak was significant but not in H/CL ratios and myocardial SUVmax.</p><p><strong>Conclusion: </strong>H/CL ratio and SUVmax/SUVpeak in 99m Tc-HMDP imaging were useful for diagnosing cardiac ATTR. Myocardial SUVpeak may be useful for monitoring changes in cardiac uptake after tafamidis treatment for cardiac ATTR.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"38-46"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142558427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low false-positive lymph nodes for 18 F-fibroblast activation protein inhibitors PET/computed tomography in preoperative staging of patients with nonsmall cell lung cancer.","authors":"Xingyu Mu, Ludeng Lu, Jingze Li, Lei Zhang, Yanyun Deng, Wei Fu","doi":"10.1097/MNM.0000000000001913","DOIUrl":"10.1097/MNM.0000000000001913","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the diagnostic accuracy of 18 F-fibroblast activation protein inhibitor (FAPI) PET/computed tomography (CT) in identifying primary tumors and mediastinal lymph node metastases in nonsmall cell lung cancer (NSCLC), with histopathological findings serving as the reference standard.</p><p><strong>Methods: </strong>Nineteen patients underwent preoperative 18 F-FAPI PET/CT and subsequent surgery; of these, 13 also underwent 18 F-fluorodeoxyglucose (FDG) PET/CT within 1 week. The diagnostic accuracy of primary tumors and lymph node metastases was evaluated for both modalities. Semiquantitative parameters, including maximum standardized uptake values (SUV max ) and target-to-background ratios (TBRs), for both primary tumors and lymph node metastases were assessed for both modalities.</p><p><strong>Results: </strong>For primary tumors, 18 of 19 (94.7%) showed positive results on 18 F-FAPI PET/CT scans. In 13 patients who also underwent 18 F-FDG PET/CT, 18 F-FAPI PET/CT demonstrated a higher detection rate compared with 18 F-FDG PET/CT (100% vs. 69.1%). The overall accuracy of lymph node assessment with 18 F-FAPI PET/CT (95.9-97.1%) was significantly higher compared to 18 F-FDG PET/CT (51.0%). Malignant lymph nodes exhibited significantly higher SUV max and TBR on 18 F-FAPI scans (SUV max : 7.0 vs. 0.9, P  < 0.001; TBR muscle : 5.0 vs. 0.8, P  < 0.001) than on 18 F-FDG scans (SUV max : 3.9 vs. 1.8, P  = 0.01), except for the liver TBR on 18 F-FDG scans (TBR liver : 1.8 vs. 1.0, P  = 0.055).</p><p><strong>Conclusion: </strong>18 F-FAPI could be utilized in the preoperative staging of NSCLC to mitigate the incidence of false positives associated with 18 F-FDG, due to its higher accuracy in identifying mediastinal lymph node metastasis.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"67-75"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency and characteristics of ectopic parathyroid adenomas in a cohort of patients referred for 18 F-fluorocholine PET/CT.","authors":"Friso M van der Zant, Maurits Wondergem, Wouter A M Broos, Sergiy V Lazarenko, Remco J J Knol","doi":"10.1097/MNM.0000000000001920","DOIUrl":"10.1097/MNM.0000000000001920","url":null,"abstract":"<p><strong>Aim: </strong>This article aimed to study the frequency and characteristics of ectopic/intrathyroidal parathyroid adenomas in patients referred for 18 F-fluorocholine PET/computed tomography (CT).</p><p><strong>Patients and methods: </strong>From 11 June 2015 to 15 January 2024, 729 patients were studied. Recorded patient variables included hyperparathyroidism type, sex, age, presence of symptoms, renal involvement, bone involvement, parathyroid hormone (PTH), and serum calcium, phosphate, and vitamin D as well as 24-h urine calcium excretion. PET/CT results were also collected. In case of parathyroidectomy, the weight of the adenomas was recorded. Continuous variables were expressed as mean ± SD. Differences were evaluated with Mann-Whitney U -tests or two-sample t -tests, when appropriate. P -values ≤0.05 were considered statistically significant.</p><p><strong>Results: </strong>PET/CT showed no adenoma in 163 (22%), adenoma in 451 (62%), hyperplasia/multiglandular disease in 32 (4%), and equivocal results in 83 (11%) patients. A total of 6/729 (1%) adenomas were located intrathyroidally and 16/729 (2%) had an ectopic location. Patients with ectopic/intrathyroidal adenoma showed significantly higher serum PTH levels than patients with no visualization of adenoma on PET. The mean mass of the adenoma was 1 ± 2.3 g in patients with orthotopic adenomas versus 2.7 ± 3.3 g in patients with ectopic/intrathyroidal adenomas; however, this was not significantly different ( P  = 0.09).</p><p><strong>Conclusion: </strong>In the presented cohort, the frequency of ectopic/intrathyroidal parathyroid adenomas was 3%. No significant difference in weight was found between orthotopic and ectopic/intrathyroidal parathyroid adenomas.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"89-94"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation exposure in vesicoureteral reflux diagnostics: a comparative study of direct radionuclide cystography and voiding cystourethrogram.","authors":"Hanna-Reeta Viljamaa, Liisi L M Ripatti, Heli R S Larjava, Tommi E J Noponen, Aleksi Saikkonen, Päivi T K Rautava, Mari A Koivisto, Niklas A Pakkasjärvi","doi":"10.1097/MNM.0000000000001918","DOIUrl":"10.1097/MNM.0000000000001918","url":null,"abstract":"<p><strong>Introduction: </strong>Voiding cystourethrography (VCUG) is the standard method for diagnosing vesicoureteral reflux (VUR) but has been criticized for radiation exposure. Direct radionuclide cystography (DRC) was developed to reduce this risk. We aimed to assess DRC's efficacy as a screening tool and compare its radiation burden to VCUG.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed patient records encompassing children who underwent VCUG or DRC to diagnose VUR from 2011 to 2020 at our hospital.</p><p><strong>Results: </strong>A total of 156 children were included (median age: 0.75 years, 53.8% females). Indications included urinary tract infection in 71.2% of patients and antenatal hydronephrosis in 26.9%. DRC was performed on 122 patients (78.2%) and VCUG on 96 patients (61.5%), with solitary use in 38.5 and 21.8% of cases, respectively, and combined application in 39.7%. DRC detected VUR in 35.3% (43/122) and VCUG in 61.5% (59/96) of patients. Bladder-filling rates differed significantly between DRC (37%) and VCUG (67%) ( P  < 0.0001). Median radiation doses were lower in VCUG (0.023 mSv) than in DRC (0.073 mSv). For patients requiring complementary VCUG after DRC, the median radiation dose for DRC was 0.063 mSv ( P  < 0.0001), resulting in a total median dose of 0.098 mSv. Cost analysis revealed VCUG as more cost-effective, with an additional expenditure of approximately 345 euros per patient undergoing DRC in our cohort.</p><p><strong>Conclusion: </strong>DRC imposed a higher radiation burden on patients than VCUG and often necessitated follow-up VCUG for positive cases. This challenges the utility of DRC as a low-radiation alternative in VUR screening.</p><p><strong>Level of evidence: </strong>Level 4: cohort study without a control group.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"15-20"},"PeriodicalIF":1.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142471827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between 18 F-FDG PET/CT metabolic parameters and microvascular invasion before liver transplantation in patients with hepatocellular carcinoma.","authors":"Fan Wu, Guohong Cao, Jinlan Lu, Shengli Ye, Xin Tang","doi":"10.1097/MNM.0000000000001897","DOIUrl":"10.1097/MNM.0000000000001897","url":null,"abstract":"<p><strong>Background: </strong>Microvascular infiltration (MVI) before liver transplantation (LT) in patients with hepatocellular carcinoma (HCC) is associated with postoperative tumor recurrence and survival. MVI is mainly assessed by pathological analysis of tissue samples, which is invasive and heterogeneous. PET/computed tomography (PET/CT) with 18 F-labeled fluorodeoxyglucose ( 18 F-FDG) as a tracer has been widely used in the examination of malignant tumors. This study investigated the association between 18 F-FDG PET/CT metabolic parameters and MVI before LT in HCC patients.</p><p><strong>Methods: </strong>About 124 HCC patients who had 18 F-FDG PET/CT examination before LT were included. The patients' clinicopathological features and 18 F-FDG PET/CT metabolic parameters were recorded. Correlations between clinicopathological features, 18 F-FDG PET/CT metabolic parameters, and MVI were analyzed. ROC curve was used to determine the optimal diagnostic cutoff value, area under the curve (AUC), sensitivity, and specificity for predictors of MVI.</p><p><strong>Result: </strong>In total 72 (58.06%) patients were detected with MVI among the 124 HCC patients. Univariate analysis showed that tumor size ( P  = 0.001), T stage ( P  < 0.001), maximum standardized uptake value (SUV max ) ( P  < 0.001), minimum standardized uptake value (SUV min ) ( P  = 0.031), mean standardized uptake value (SUV mean ) ( P  = 0.001), peak standardized uptake value (SUV peak ) ( P  = 0.001), tumor-to-liver ratio (SUV ratio ) ( P  = 0.010), total lesion glycolysis (TLG) ( P  = 0.006), metabolic tumor volume (MTV) ( P  = 0.011) and MVI were significantly different. Multivariate logistic regression showed that tumor size ( P  = 0.018), T stage ( P  = 0.017), TLG ( P  = 0.023), and MTV ( P  = 0.015) were independent predictors of MVI. In the receiver operating characteristic curve, TLG predicted MVI with an AUC value of 0.645. MTV predicted MVI with an AUC value of 0.635. Patients with tumor size ≥5 cm, T3-4, TLG > 400.67, and MTV > 80.58 had a higher incidence of MVI.</p><p><strong>Conclusion: </strong>18 F-FDG PET/CT metabolic parameters correlate with MVI and may be used as a noninvasive technique to predict MVI before LT in HCC patients.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1033-1038"},"PeriodicalIF":1.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parametric imaging in salivary gland scintigraphy.","authors":"Rogério Anton Faria, Graziella Chagas Jaguar, Eduardo Nóbrega Pereira Lima","doi":"10.1097/MNM.0000000000001901","DOIUrl":"10.1097/MNM.0000000000001901","url":null,"abstract":"<p><p>Salivary gland scintigraphy (SGS) is an imaging technique to evaluate functional aspects of the salivary glands. First described in 1965, visual analyses of summed images and of time-activity curves generated through regions of interest (ROI) are still the main evaluation tools used in clinical practice. An alternative to ROI-based analysis is the use of parametric images, which are images generated through pixel-by-pixel calculation of parameters from the original frames. In this article, we would like to present some parametric images for SGS studies and how to create and use them. Two images, vascular flow and uptake velocity, were created using the intercept and slope of a linear model of the frames from after the first to fifth minute of acquisition. And two others, excretion fraction and absolute excretion, by subtraction and division methods of the frames before and after sialogogue stimulation. These images allow the visualization of the spatial distribution and heterogeneity of these quantitative parameters, favoring different forms of analysis and helping with image segmentation. After more than a year of using these images in daily routine, our general impression is that they have been very helpful. This article, however, still represents only our early experiences with this technique, and clinical studies are yet needed to better evaluate this method.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1098-1104"},"PeriodicalIF":1.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SeHCAT retention measurements may be compromised by traces of 177 Lu/ 177m Lu more than 90 days after 177 Lu-DOTATATE was administered.","authors":"Tamar Willson, Richard Meades","doi":"10.1097/MNM.0000000000001903","DOIUrl":"10.1097/MNM.0000000000001903","url":null,"abstract":"<p><p>[ 75 Se]tauroselcholic acid (SeHCAT) retention measurement provides a noninvasive test for bile acid diarrhea (BAD); however, it is sensitive to the presence of other radionuclides. Two SeHCAT patients at the Royal Free Hospital (RFH) had significant discrepancies between the lower photopeak (111-159 keV) and central photopeak (242-296 keV) windows, indicating contamination with a radionuclide other than 75 Selenium. These patients had received lutetium-177 oxodotreotide ( 177 Lu-DOTATATE) therapy 98 and 151 days before their SeHCAT tests. Traces of 177 Lu may be retained longer than typically modeled, along with the contaminant 177m Lu. This work includes a retrospective audit to examine the prevalence of SeHCAT tests being affected by 177 Lu and phantom measurements to investigate the potential impact. Of 579 patients who received 177 Lu-DOTATATE therapy at our center, 11 subsequently attended for a SeHCAT test. The two previously identified patients may have had compromised SeHCAT results; however, the other patients had longer intervals between their therapy and test, and their tests are believed to be valid. Spectra were acquired from a phantom containing either a SeHCAT capsule or a mixture of 177 Lu/ 177m Lu representative of a patient >90 days after their treatment. The SeHCAT spectrum was scaled to produce simulated day-7 spectra, and the SeHCAT retention that would have been calculated if 177 Lu/ 177m Lu were present was determined. All SeHCAT measurement windows are affected by the 177 Lu/ 177m Lu, producing clinically significant errors. Patients requiring SeHCAT testing should be asked whether they have ever received 177 Lu-DOTATATE. Patient-specific background measurements may be useful for checking for significant levels of other radionuclides.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1092-1097"},"PeriodicalIF":1.3,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142292867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}